Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

Data Presented at ASCO Breast Cancer Symposium; Additional Positive Results

Seen Since Presentation at ASCO Annual Meeting in June Phase I Trial Expanding to Include Alvespimycin Plus Trastuzumab Plus

Paclitaxel Regimen

HAYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated antitumor activity and tolerability in combination with trastuzumab (Herceptin(R)) in patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Data from the ongoing trial in patients with solid tumors were presented on Friday, September 7, 2007 by Shanu Modi, M.D., Memorial Sloan Kettering Cancer Center, in a poster, titled, "Alvespimycin (KOS-1022) and Trastuzumab (T): Activity in HER2+ Metastatic Breast Cancer (MBC)" at the 2007 Breast Cancer Symposium of the American Society of Clinical Oncology (ASCO), San Francisco, CA.

"Alvespimycin continues to demonstrate meaningful antitumor activity in patients with highly refractory HER2-positive metastatic breast cancer and ovarian cancer, with additional positive Phase 1 data showing sustained responses and clinical benefit," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Our strategy is to pursue potentially a broad and fast-to-market development pathway for alvespimycin in HER2-positive metastatic breast cancer. We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establish a saf
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PARK,Md.,Nov.25/PRNewswire-USNewswire/--RemediumTe...efoamthatstopsseverebleeding,wonfirstprizeand$10,0...lSecurityChallenge2009,companyofficialsannouncetod...theworld,Remedium,steampitchedtheirinventionattheG...usiness. ,, Remedium( www.remediumtechnologies....
(Date:11/25/2009)...China,Nov.25/PRNewswire-Asia-FirstCall/--ChinaSkyO...)(Nasdaq: CSKI ),a,leadingfullyintegratedpharmaceu...rdrugsinthePeople,sRepublicofChina("PRC"),today,an...nalInstitutefor,theControlofPharmaceuticalandBiolo...oducts:itsDiagnosticKitforHumanProstateSpecific,An...
(Date:11/25/2009)...TY,Calif.,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc...ingpoint-of-carebloodanalysissystems,announcedtoda...r,willpresentatthe21stAnnualPiperJaffrayHealthCare...heconferencewillbeheldattheNewYorkPalaceHotelinNew...,manufacturesandmarketsportablebloodanalysissystem...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Treating Workers Mental Woes May Boost Productivity 56746 1Treating Workers Mental Woes May Boost Productivity 56746 2Wings of Mercy Benefit Features Miracle on the Hudson Heroes 56743 1Wings of Mercy Benefit Features Miracle on the Hudson Heroes 56743 2Wings of Mercy Benefit Features Miracle on the Hudson Heroes 56743 3QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 1QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 2QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 3QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 4
... GlaxoSmithKline (NYSE: GSK ),announced positive...d placebo-,controlled ITP Study with Eltrombopag),... adults with chronic immune (idiopathic) thrombocy... prior ITP therapies. Patients,receiving PROMACTA ... to,maintain platelet counts between 50,000 to 400...
...Bayer HealthCare Pharmaceuticals Inc. announced to...ine(R) (sargramostim) will be presented at the 50t...logy (ASH) from December 6-9, 2008 in San Francisc...m leading oncology and hematology research centers... presentations reporting important findings in leu...
Other Medicine Technology:GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 2GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 3GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 4GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 6GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 7GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 8Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 2Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 3Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 4Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 5Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 6
(Date:11/25/2009)...vidence of a statistically significant survival be... estrogen receptor (ER)-positive tumors had high l...8 (ER-alpha S118-P), according to a brief communic... of the National Cancer Institute . , Approximat...xifen. Preclinical studies have shown that ER-alph...
(Date:11/25/2009)... fight rheumatoid arthritis, could help newly diag...AY, Nov. 25 (HealthDay News) -- A drug commonly us...arthritis now also shows some promise in helping p... The drug, rituximab (Rituxan), helped patients ke...h the disease had destroyed some of their pancreat...
(Date:11/25/2009)... sees few signs of trouble with the H1N1 vaccine,... -- The ongoing H1N1 swine flu pandemic may be dri...younger patients, a U.S. health official said Wedn...pneumococcal infections around the country," Dr. A...Immunization and Respiratory Diseases at the U.S. ...
(Date:11/25/2009)...ncer vaccine carried into the body on a carefully ...to successfully eliminate tumors in mammals, scien...nslational Medicine . , The new approach, pionee...niversity, uses plastic disks impregnated with tum...to reprogram the mammalian immune system to attack...
(Date:11/25/2009)...n flesh that mimicked parts of speech colored perc...(HealthDay News) -- People can "hear" not only wit...ch shows. , In fact, sensations on the skin des...lped people decipher sounds better, the Canadian s...show whether we could use tactile information in t...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3
...r Martin Watterson and team from Northwestern Univ...ew compound called MW01-5-188WH which has been fou... Cytokines which leads to activation of glia, whic...lzheimer’s disease is characterized by loss in mem...
...ria parasites can develop in the lymph nodes also,...ard. This reportedly has implications for the mamm...se is caused when a mosquito infected with Plasmod...s and infect red blood cells, beginning the onset ...
...published in the Journal of Infectious Diseases ha...f Staphylococcus aureus in nasal samples, // among...ive factor in a majority of the hospital acquired ...n the US. About 1% of the nasal samples test...
...r Rosemary Crompton conducted a survey in 5 Europe...ween work life and domestic life // to find out w... would like to have a traditional life style, the ... Researchers found that women who worked hard...
...n who underwent the world’s first face transplant ...hospital. Doctors say that she is increasing the r... Isabelle Dinoire, 38, hailing from France was...e donor of the face was a 46-year old teacher who ...
...k antibiotic drug which is used for treating lung ... failure, according to a report. //Medical practit...aid that they found three cases of liver failure i...f each other last year, said report co-author John...
Other Medicine News:Health News:Malaria Can Develop In Lymph Nodes Also 2Health News:90 Million Americans Harbor Drug Resistant Bacteria Inside Their Nose 2
Liquichek Urinalysis Control
qUAntify Plus Control
Lyphochek Fertility Control
Liquichek Spinal Fluid Control
Medicine Products: